Open Access
Subscription or Fee Access
A Review on Corticosteroids: A Controversial Role in COVID-19
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the known causative agent of coronavirus disease 2019 (COVID-19) which emerged first in Wuhan Province of China has caused catastrophic health, social, and economic crisis worldwide. Several drug therapies were used with corticosteroids being one of them, believing to exert an effect in controlling the ARDS. Use of corticosteroids in patients with COVID-19 is common in clinical practice, but the efficacy and role still remains a major controversy. Most of the studies suggest that methylprednisolone when given in the Intravenous route of with the dose of 0.5-1mg/kg has showed the positive response by decreasing the mortality rate in elderly patients, has shown good benefit in patients with excessive inflammation, improved the survival outcome, decreased the requirement for mechanical ventilation, decreased the hospital stay. It is important to make a careful decision when administering corticosteroids, making it certain that the benefits outweigh the risks. Further studies have to be conducted to study the role of corticosteroids which will helps to stipulate the Rational Therapy.
Keywords
References
WHO. (2022, Jan.) WHO Coronavirus (COVID-19) Dashboard [Online]. Available from https://covid19.who.int/. [Accessed April. 9, 2022].
Sreeja Nyayakar, Srinivasan R, Archana L, Nithyanandan S. A Cross-Sectional Study on Acceptance and Post-Vaccination Symptoms of Covid-19 Vaccination In India. Asian journal of pharmaceutical and clinical Research. 2022; 15 (1): 1–4.
Jeronimo CMP, Farias MEL, Val FFA, e.al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized with Coronavirus Disease 2019 (COVID-19; Metcovid): A Randomized, Double-blind, Phase IIb, Placebo-controlled Trial. Clinical Infectious Diseases. 2021; 72 (9): 373–381.
Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients with Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19. JAMA. 2020; 324 (13):1307–16.
Ramamoorthy S, Cidlowski JA. Mechanisms of Action in Health and Disease. Rheum Dis Clin North Am. 2016; 42 (1):15–31.
Wu J, Huang J, Zhu G, et al. Systemic Corticosteroids and Mortality in Severe and Critical COVID-19 Patients in Wuhan, China. The Journal of Clinical Endocrinology & Metabolism. 2020; 105 (12): 4230–4239.
Fadel R, Morrison AR, Vahia A, et.al. Early Short-Course Corticosteroids in Hospitalized Patients with COVID-19. Clinical Infectious Diseases. 2020; 71 (16): 2114–2120.
Li Y, Meng Q, Rao X, et al. Corticosteroid therapy in critically ill patients with COVID-19: a multicentre, retrospective study. Critical Care. 2020; 24 (1):698.
Zhou W, Yisi L, Dongdong T, Cheng W, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduction and Targeted Therapy. 2020; 5 (1): 1–3.
Russell B, Charlotte M, Anne R, and Mieke VH. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancer medical science. 2020; 14: 1023.
Li Q, Li W, Jin Y, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: A retrospective cohort study. 2020; 9 (4): 823–36.
Li Y, Zhou X, Li T, et al. Corticosteroid prevents COVID-19 progression within its therapeutic window: a multicentre, proof-of-concept, observational study. emerging microbes & infections. 2020; 9 (1): 1869–77.
Liu J, Zhang S, Dong X, et al. Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome. 2020; 130 (12): 6417–28.
Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: A meta-analysis: A meta-analysis. 2019; 98 (26):e16239.
Ma Y, Zeng H, Zhan Z, et al. Corticosteroid use in the treatment of COVID-19: A multicenter retrospective study in Hunan, China. 2020; 11: 1198.
Dequin P-F, Heming N, Meziani F, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: A randomized clinical trial: A randomized clinical trial. Jama. 2020; 324 (13): 1298–306.
Nasim S, Kumar S, Azim D, Ashraf Z, Azeem Q. Corticosteroid use for 2019-nCoV infection: A double-edged sword. 2020; 41 (10): 1244–5.
Li S, Hu Z, Song X. High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19. 2021; 72 (7): 1297–8.
Refbacks
- There are currently no refbacks.
Copyright (c) 2022 Research & Reviews: A Journal of Health Professions